Progress in approved drugs from natural product resources

被引：128
作者：
Luo, Zhongwen [1 ]
Yin, Fucheng [1 ]
Wang, Xiaobing [1 ]
Kong, Lingyi [1 ]
机构：
[1] China Pharmaceut Univ, Sch Tradit Chinese Pharm, State Key Lab Nat Med, Nanjing 211198, Peoples R China
来源：
CHINESE JOURNAL OF NATURAL MEDICINES | 2024年 / 22卷 / 03期
基金：
中国国家自然科学基金;
关键词：
New drugs; Natural products; Structural modification; CYCLOSPORINE-A; ANISODAMINE; HOMOHARRINGTONINE; CLARITHROMYCIN; TELITHROMYCIN; GALANTHAMINE; AZITHROMYCIN; PHARMACOLOGY; TACROLIMUS; LOVASTATIN;
D O I：
10.1016/S1875-5364(24)60582-0
中图分类号：
R [医药、卫生];
学科分类号：
10 ;
摘要：
Natural products (NPs) have consistently played a pivotal role in pharmaceutical research, exerting profound impacts on the treatment of human diseases. A significant proportion of approved molecular entity drugs are either directly derived from NPs or indirectly through modifications of NPs. This review presents an overview of NP drugs recently approved in China, the United States, and other countries, spanning various disease categories, including cancers, cardiovascular and cerebrovascular diseases, central nervous system disorders, and infectious diseases. The article provides a succinct introduction to the origin, activity, development process, approval details, and mechanism of action of these NP drugs.
引用
收藏
页码：195 / 211
页数：17
相关论文
共 119 条
[1]   Milk Thistle in Liver Diseases: Past, Present, Future [J].
Abenavoli, Ludovico ;
Capasso, Raffaele ;
Milic, Natasa ;
Capasso, Francesco .
PHYTOTHERAPY RESEARCH, 2010, 24 (10) :1423-1432
[2]   Erythromycin, clarithromycin, and azithromycin: Are the differences real? [J].
Amsden, GW .
CLINICAL THERAPEUTICS, 1996, 18 (01) :56-72
[3]  
[Anonymous], New Drugs at FDA: CDERs New Molecular Entities and New Therapeutic Biological Products
[4]  
[Anonymous], 1978, Chin Tradit Herbal Drugs, P49
[5]  
[Anonymous], 2020, Drug Approvals and Databases: Additions and Deletions for Prescription and OTC Drug Product Lists
[6]  
[Anonymous], 1978, Chin Tradit Herbal Drugs, P23
[7]   Intratumoral Comparison of Nanoparticle Entrapped Docetaxel (CPC634) with Conventional Docetaxel in Patients with Solid Tumors [J].
Atrafi, Florence ;
van Eerden, Ruben A. G. ;
Vlieg, Marte A. M. van Hylckama ;
Oomen-de Hoop, Esther ;
de Bruijn, Peter ;
Lolkema, Martijn P. ;
Moelker, Adriaan ;
Rijcken, Cristianne J. ;
Hanssen, Rob ;
Sparreboom, Alex ;
Eskens, Ferry A. L. M. ;
Mathijssen, Ron H. J. ;
Koolen, Stijn L. W. .
CLINICAL CANCER RESEARCH, 2020, 26 (14) :3537-3545
[8]  
Bailey CJ., 2004, Pract Diab Int, V21, P115, DOI DOI 10.1002/PDI.606
[9]   Metformin: historical overview [J].
Bailey, Clifford J. .
DIABETOLOGIA, 2017, 60 (09) :1566-1576
[10]   Molecular and cellular basis of the anticancer activity of the prenylated flavonoid icaritin in hepatocellular carcinoma [J].
Bailly, Christian .
CHEMICO-BIOLOGICAL INTERACTIONS, 2020, 325
12345678910